Substance Use Disorders Clinical Trial
Official title:
Sociodemographic and Clinical Characteristics of Patients Admitted to the Addiction Management Unit of Assiut University Hospital
Substance use disorder (SUD) is a dynamic process that changes constantly over time with new trends of drug dependence emerge every now and then, thus timely information about trends in psychoactive substance use could yield tailored interventions and reduce potential harms. Identifying personal, social, and demographic characteristics of patients with this disorder at the local, regional, and national levels helps physicians, health authorities, and policy-makers detect early emerging trends and enable them better plan and implement prevention, treatment, and rehabilitation programs. This study aims to identify sociodemographic, personal characteristics, as well as patterns of illicit drug abuse in patients admitted for addiction treatment.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | May 2024 |
Est. primary completion date | April 12, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - All patients with substance use disorder who are admitted to the addiction treatment unit. - Accept participating into the study. Exclusion Criteria: - Patients refuse participating in the study. |
Country | Name | City | State |
---|---|---|---|
Egypt | Assiut University Hospital | Assiut | Assiut Governorate |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Egypt,
Connery HS, McHugh RK, Reilly M, Shin S, Greenfield SF. Substance Use Disorders in Global Mental Health Delivery: Epidemiology, Treatment Gap, and Implementation of Evidence-Based Treatments. Harv Rev Psychiatry. 2020 Sep/Oct;28(5):316-327. doi: 10.1097/HRP.0000000000000271. — View Citation
Darweesh, A. E., Agban, M., Mohammed, M. H., & Gabra, R. H. (2020). Association between opioid use disorder (tramadol) and serum level of interleukin-2. Middle East Current Psychiatry, 27(1). https://doi.org/10.1186/s43045-020-00037-w
Loffredo CA, Boulos DN, Saleh DA, Jillson IA, Garas M, Loza N, Samuel P, Shaker YE, Ostrowski MJ, Amr S. Substance use by Egyptian youth: current patterns and potential avenues for prevention. Subst Use Misuse. 2015 Apr;50(5):609-18. doi: 10.3109/10826084.2014.997391. Epub 2015 Jan 28. — View Citation
Rabie, M., Shaker, N.M., Gaber, E. et al. Prevalence updates of substance use among Egyptian adolescents. Middle East Curr Psychiatry 27, 4 (2020). https://doi.org/10.1186/s43045-019-0013-8
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To identify the sociodemographic characteristics of patients with substance use disorder attending addiction treatment unit. | Sociodemographic characteristics with a special prepared survey that includes: Personal information, and socioeconomic status.(Age, gender, marital status, work, income, educational level, ...etc) Previous admissions/trials for detox.(number of previous admissions/trials detox, where they were, maximum abstinence time, and the withdrawal symptoms the patient had) Medical, psychological, social, financial, and legal aspects of addiction. Adverse life events dating before starting addiction. Detailed description of substance(s) used.( Substances used, doses, route of administration, when, where, and with whom he prefers taking the drug) Psychiatric interview. |
One week | |
Primary | To identify personality traits of patients with substance use disorder attending addiction treatment unit. | Data about personality traits of patients with substance use disorder will be obtained through: Psychiatric interview. The Symptom Checklist-90-Revised (SCL-90-R). The Five-Factor Model of Personality. |
One week | |
Primary | To identify patterns of substance abuse among patients with substance use disorder attending addiction treatment unit. | Data about patterns of substance abuse will be gathered through: Psychiatric interview. Severity of Dependence Scale (SDS). Urine Drug Screen. |
One week |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05660434 -
Using Aromatherapy in Substance Use Disorder
|
N/A | |
Active, not recruiting |
NCT05338268 -
Substance Use and Loneliness
|
N/A | |
Completed |
NCT03954184 -
E-health Implementation (Iowa)
|
N/A | |
Completed |
NCT04098614 -
Barriers to Substance Use Disorder Recovery
|
N/A | |
Completed |
NCT03590106 -
Cardiac Surgery Peer Recovery Support Program
|
N/A | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Recruiting |
NCT06273228 -
Parenting Young Children in Pediatrics
|
N/A | |
Recruiting |
NCT05327504 -
Written Exposure Therapy for Veterans With SUD and PTSD
|
N/A | |
Terminated |
NCT03517111 -
The Impact of a Parenting Intervention on Latino Youth Health Behaviors
|
N/A | |
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Completed |
NCT04401215 -
Technologically-Augmented Referrals to Mitigate Addiction Consequences
|
N/A | |
Not yet recruiting |
NCT06163651 -
Evaluating a One-Year Version of the Parent-Child Assistance Program
|
N/A | |
Not yet recruiting |
NCT06187701 -
Co-Active Therapeutic Theatre (Co-ATT) for Dual-Diagnosis Patients
|
N/A | |
Recruiting |
NCT04296604 -
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
|
N/A | |
Active, not recruiting |
NCT02382042 -
Intensive Referral Intervention to Improve Substance Use Disorder Treatment Outcomes Among Rural and Highly Rural Veterans
|
N/A | |
Completed |
NCT01237366 -
Study Targeting Affect Regulation
|
Phase 1/Phase 2 | |
Terminated |
NCT01356667 -
Drum-Assisted Therapy for Native Americans
|
N/A | |
Completed |
NCT00708890 -
Twelve Step Based Self-help Groups for Substance Related Disorders
|
N/A | |
Active, not recruiting |
NCT04048850 -
Zepatier in Patients With Substance Use
|
||
Recruiting |
NCT05976646 -
Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion
|
Phase 1/Phase 2 |